End-stage liver fibrosis frequently progresses to portal vein thrombosis, formation of oesophageal varices, hepatic encephalopathy, ascites, hepatocellular carcinoma and liver failure. Mesenchymal stem cells (MSCs), when transplanted in vivo, migrate into fibrogenic livers and then differentiate into hepatocyte-like cells or fuse with hepatocytes to protect liver function. Moreover, they can produce various growth factors and cytokines with anti-inflammatory effects to reverse the fibrotic state of the liver. In addition, only a small number of MSCs migrate to the injured tissue after cell transplantation; consequently, multiple studies have investigated effective strategies to improve the survival rate and activity of MSCs for the treatment of liver fibrosis. In this review, we intend to arrange and analyse the current evidence related to MSC transplantation in liver fibrosis, to summarize the detailed mechanisms of MSC transplantation for the reversal of liver fibrosis and to discuss new strategies for this treatment. Finally, and most importantly, we will identify the current problems with MSC-based therapies to repair liver fibrosis that must be addressed in order to develop safer and more effective routes for MSC transplantation. In this way, it will soon be possible to significantly improve the therapeutic effects of MSC transplantation for liver regeneration, as well as enhance the quality of life and prolong the survival time of patients with liver fibrosis.
| INTRODUCTION
The liver is a digestive organ that stores glycogen, scavenges toxins and participates in protein synthesis for metabolic homeostasis.
Because it makes direct contact with external toxins, the liver is easily injured under stress conditions. In response to repeated and chronic liver injury induced by hepatitis B virus (HBV), hepatitis C virus (HCV), sustained alcohol consumption and fat deposition, [1] [2] [3] [4] the liver can accumulate aberrant myofibroblasts and extracellular matrix, thus generating liver fibrosis with poor prognosis. The pathogeneses of primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis are very different from other types of chronic liver fibrosis, as portal fibroblasts are found around bile ducts. 5 Intriguingly, schistosomiasis induces liver fibrosis through accumulation of parasitic ova and periovular granulomas in portal veins. 6 Hepatolenticular degeneration, known as Wilson's disease, accounts for a small proportion of metabolic liver diseases. It is caused by a mutation in the Wilson disease protein (ATP7B) gene and frequently leads to liver fibrosis. 7 In addition, metabolic syndromes including obesity, insulin resistance and diabetes have recently been found to be closely related to end-stage liver fibrosis. 8 Although the mortality of liver cirrhosis varies substantially across different regions of the world, it has been universally acknowledged by multiple investigators that liver cirrhosis has gradually become an increasing health burden worldwide, as liver cirrhosis and other chronic liver diseases contributed to 2% of deaths worldwide in 2015, with a relative increase of 10.3% from 2005. 9 They also highlighted that the increasing mortality mainly attributed to viral hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease in developed countries. 9 The long-term inflammatory response and fibrotic state induced by various factors leads to other complications, including hepatocellular carcinoma (HCC) and liver failure. ing neovascularization in liver tissues. 10 However, it is hard to regress more significant liver fibrosis (cirrhosis), thus an intervention that targets the fibrosis is needed. Considering that MSCs have abundant resources, strong proliferative ability, multilineage potential and no ethical considerations for widespread application to repair various organ injuries, they are currently transplanted in vivo to reduce hepatocyte apoptosis and promote hepatocyte regeneration. 11 Before application, the isolated and purified MSCs must met three criteria according to the International Society for Cellular Ther- 
| POTENTIAL MECHAN ISMS
Chronic liver injury induces liver fibrosis via up-regulating the accumulation of extracellular matrix in vivo, and then normal hepatic architecture is replaced by a nodular structure of fibrous septa. In general, myofibroblasts are the major source of extracellular matrix,
HSCs are considered to be the principal precursor population for myofibroblasts. Because liver tissue consists of multiple cell types, in vitro studies do not completely mimic the complex situation of the liver, but animal models can be used as a gold standard for in vivo study. A majority of studies investigated the potential mechanisms of MSC and MSC derivative-based therapies in liver fibrosis for enhancing the therapeutic effects ( Figure 1 ). 30 Zhong et al detected no signal change in the vena caudalis group by magnetic resonance imaging, but they showed that MSC migration was gradually increased after immediate transplantation and decreased gradually after 3-hour transplantation through portal vein route. Then, MSC signals disappeared in tissues around portal area while appeared in fibrous tuberculum at the edge of the liver at day 14 after transplantation. They concluded that portal vein route seemed to be more beneficial than the vena caudalis route on MSC migration to fibrotic liver. 33 According to current studies, the majority of investigators accept that portal vein route seems to be the best choice for MSC transplantation. However, the optimal route for transplantation in animal models still needs to be further investigated to achieve better effects in clinical trials. and increased the level of MMP-9 to a greater degree than bone marrow-derived MSCs. 34 Rengasamy et al suggested that bone marrow-derived MSCs were more effective in reducing liver fibrosis than
| SOURCES OF MSCS
Wharton's jelly-derived MSCs in CCl 4 -induced liver fibrotic rats, as
shown by lower levels of α-SMA, higher levels of MMP-1 and greater activation of hepatic progenitor cells in rats treated with bone marrow-derived MSCs. 35 Hao et al found that adipose-derived
MSCs achieved greater reductions of the proliferation and activation of HSCs and secreted higher levels of nerve growth factor and TGF-β1 in the cell culture medium than bone marrow-derived MSCs.
They also found that although adipose-derived MSCs improved antiinflammatory and anti-fibrotic effects than bone marrow-derived MSCs, the differences in inflammatory activity and fibrosis staging scores were not significant. Thus, they concluded that bone marrowderived MSCs and adipose-derived MSCs are similarly effective at attenuating liver fibrosis. 36 In contrast, Baligar et al demonstrated that bone marrow-derived CD45 + MSCs had better anti-fibrotic ability than adipose-derived MSCs because they expressed higher levels of MMP-9 and MMP-13 and inhibited HSC proliferation more effectively. 37 Most comparisons were conducted between bone marrowderived MSCs and other MSCs, while the optimal choice is still undetermined for treating liver fibrosis. To this end, we want to highlight that bone marrow-derived MSCs are applied as the main source of MSC transplantation, hence, we call for more studies to compare the advantages and disadvantages among MSCs from various resources. showing that these cells had higher homing rates and stronger effects on recovery from liver fibrosis than undifferentiated MSCs. 40 However, there is still controversy surrounding the beneficial effects of these two kinds of cell transplantation. MSCs are more effective in maintaining liver function compared with hepatogenic MSCs, although both of them can effectively reverse liver fibrosis in a rat model. 41 The use of secretome derived from MSCs or conditioned media to reduce liver fibrosis has gradually become a hot topic in current regenerative medicine. The secretome is a special set of factors (soluble proteins, free nucleic acids, lipids and extracellular vesicles) secreted into the extracellular space and changes in response to fluctuations in various conditions. 42 Cell-free secretome isolated from MSCs exerted antifibrotic effects by inhibiting activation of TGF-β/ Smad signalling and HSCs. 43 Exosomes, which are small (30- (Table 1) .
| MSC-DERIVE D SOURCES

| PRETREATMENT OR COTREATMENT OF MSCS
Although hypoxia has been proved to activate STAT3/hypoxia-in- 
| PRECONDITIONING OF RECIPIENTS
In recent years, multiple strategies focusing on the preconditioning of recipients have been developed to improve the efficiency of MSCs in repairing liver injury and reversing liver fibrosis. Splenectomy prior to MSC transplantation can improve liver function and suppress fibrotic progression more efficiently than MSC transplantation alone by improving the migration rate of MSCs and up-regulating plasma SDF-1α and serum HGF in liver cirrhosis patients. 60 Liver fibrotic rats received a hepatic irradiation preconditioning before Finally, some pretreatments or cotreatments may be tested in recipients to improve the therapeutic effects of MSC transplantation for the repair of liver injury in liver fibrosis.
| GENE MODIFICATION
Gene modulation is generally applied to reprogram somatic cells into a stemness state, and it can effectively enhance the effects of MSC transplantation in liver fibrotic models as well (Table 2) .
Considering the important role of TIMP-1 in liver fibrosis progression, lentiviral vector-mediated silencing of TIMP-1 in MSCs significantly reduced fibrotic area and collagen deposition in a rat model of liver fibrosis. 66 In addition, MSCs transfected with MMP-1 enhanced the reduction of liver fibrosis than MSC group by downregulating collagen content and inhibiting activation of HSCs. | 1665 repair liver dysfunction, the low efficacy of genetic modification and its potential for tumourigenicity may limit its application.
| CLINICAL TRIALS
Investigators focus on developing new method to improve MSC efficiency in vivo in animal models with liver cirrhosis, but the real effects should be estimated by clinical trials (Table 3 decrease in the levels of TGF-β1, COL1A1 and α-SMA. 82 In addition, 72 patients with alcoholic cirrhosis were enrolled for MSC transplantation, and although one-time and two-time transplantation reduced collagen deposition by 25% and 37%, respectively, there was no significant difference in fibrosis quantification between the two groups. 83 
| CONCLUSIONS
Long-term exposure to viral hepatitis, toxic chemicals, alcohol, lipid deposition, parasites or autoimmune elements in human and animals lead to liver fibrosis with a poor prognosis. The imbalance between MMPs and F I G U R E 2 Drugs, liver transplantation, hepatocyte transplantation and stem cell transplantation can be applied to liver fibrosis induced by multiple toxic factors
TIMPs is a key contributor to the pathogenesis of liver fibrosis, and HSC activation also plays a vital role in its progression. Drugs, liver transplanta- 
